A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Phase of Trial: Phase I
Latest Information Update: 14 May 2019
Price : $35 *
At a glance
- Drugs CGX 1321 (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Curegenix
- 09 May 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 09 May 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
- 27 Apr 2018 New trial record